Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | DUT | P33316 | 2/20 | 0.48 |
| ▸ | TK2 | O00142 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TK1 | P04183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26176904 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL26176883 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL26176911 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL26176881 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL24207815 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL3190599 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL24207971 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL4454711 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL3485522 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL26176900 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114305-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | SANOFI (FR) | 2025-04-10 | — | — | US | disclosed |
| US-12030833-B2 | Method for producing hetero-type monodisperse polyethylene glycol derivative | NOF CORPORATION (JP) | 2024-07-09 | — | — | US | disclosed |
| US-11945838-B2 | Method for synthesis of protein amphiphiles | INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH (IN) | 2024-04-02 | — | — | US | disclosed |
| CN-117186436-A | Preparation method and application of metal organic framework glass with adjustable specific surface area | 上海科技大学 | 2023-12-08 | — | — | CN | disclosed |
| CN-117126095-A | Releasable functional compound containing polyethylene glycol chain segment with single molecular weight, nanoparticle containing same and preparation method | 中国科学技术大学 | 2023-11-28 | — | — | CN | disclosed |
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| US-11680137-B2 | Method for purifying trityl group-containing monodispersed polyethylene glycol | NOF CORPORATION (JP) | 2023-06-20 | — | — | US | disclosed |
| EP-4182302-A1 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | Sanofi Pasteur (FR) | 2023-05-24 | — | — | EP | disclosed |
| EP-4182296-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | Sanofi Pasteur (FR) | 2023-05-24 | — | — | EP | disclosed |
| US-7476709-B2 | Process for preparing oligonucleotides | AVECIA BIOTECHNOLOGY INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7365132-B2 | Monomers containing polyoxyalkylenes and polymer supports therefrom | AVECIA BIOTECHNOLOGY INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20060149052-A1 | Process for the preparation of oligonucleotides | AVECIA LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| US-20060036028-A1 | Process for preparing oligonucleotides | NITTO DENKO AVECIA, INC. | 2006-02-16 | — | — | US | disclosed |
| US-20050256283-A1 | Monomers containing polyoxyalkylenes and polymer supports therefrom | NITTO DENKO AVECIA, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050245446-A1 | Materials for the delivery of biologically-active material to cells | NANOGENICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
| EP-1504049-A1 | MONOMERS CONTAINING POLYOXYALKYLENES AND POLYMER SUPPORTS THEREFROM | Avecia Limited (GB) | 2005-02-09 | — | — | EP | disclosed |
| EP-1501851-A1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | Avecia Limited (GB) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091311-A1 | MONOMERS CONTAINING POLYOXYALKYLENES AND POLYMER SUPPORTS THEREFROM | AVECIA LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003091267-A1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245446-A1 | Materials for the delivery of biologically-active material to cells | ITGB1, ITGA2B, ITGB2 | KIF11 2529/4885DUT 1642/4885TK2 1292/4885 |
| US-20060036028-A1 | Process for preparing oligonucleotides | RTCB, POLRMT, POLM | KIF11 1073/4885DUT 166/4885TK2 344/4885 |
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | MTTP, CETP, LNPEP | KIF11 2133/4885DUT 669/4885TK2 2315/4885 |
| US-20250114305-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | NR1H2, NR1H3, LPAR3 | KIF11 4483/4885DUT 4037/4885TK2 2738/4885 |
| US-12030833-B2 | Method for producing hetero-type monodisperse polyethylene glycol derivative | DDT, DDC, FGFR2 | KIF11 879/4885DUT 153/4885TK2 1349/4885 |
| US-20060149052-A1 | Process for the preparation of oligonucleotides | CPSF7, CPSF1, CPSF6 | KIF11 2201/4885DUT 535/4885TK2 414/4885 |
| US-11945838-B2 | Method for synthesis of protein amphiphiles | PTMS, VAC14, PDIA6 | KIF11 3691/4885DUT 2334/4885TK2 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.